Decreased Fibrogenesis after Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis

Inflammatory Bowel Diseases

Volumn 22, Issue 3, 2016, Pages 569-582

  Meier, Remo ^a   Lutz, Christian ^a   Cosin Roger, Jesus ^a,b   Fagagnini, Stefania ^a   Bollmann, Gabi ^a   Hunerwadel, Anouk ^a   Mamie, Celine ^a   Lang, Silvia ^a   Tchouboukov, Alexander ^c   Weber, Franz E ^c   Weber, Achim ^a   Rogler, Gerhard ^a   Hausmann, Martin ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Fibrogenesis; fibrosis; graft; intestinal; MMP 9; mouse model; pirfenidone; TGF ; transplantation; treatment

Indexed keywords

COLLAGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; ENZYME IMMUNOASSAY; FEMALE; FIBROSIS; INTESTINAL DISEASES; METABOLISM; MOUSE; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL PROLIFERATION; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; IMMUNOENZYME TECHNIQUES; INTESTINAL DISEASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84959358311     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000716     Document Type: Article

References (48)

1. Jones MK, Tomikawa M, Mohajer B, et al. Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci. 1999;4:D303-D309.
2. Rieder F, Brenmoehl J, Leeb S, et al. Wound healing and fibrosis in intestinal disease. Gut. 2007;56:130-139.
3. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am. 1995; 24:475-507.
4. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006;3:383-388.
5. Kim H, Oda T, Lopez-Guisa J, et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2001; 12:736-748.
6. Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol. 2000;279: L895-L902.
7. Vaillant B, Chiaramonte MG, Cheever AW, et al. Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol. 2001; 167:7017-7026.
8. Bucala R, Spiegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1:71-81.
9. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
10. Freeman HJ. Natural history and clinical behavior of Crohn's disease extending beyond two decades. J Clin Gastroenterol. 2003;37:216-219.
11. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999;50: 667-671.
12. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12.
13. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241.
14. Johnson LA, Luke A, Sauder K, et al. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "Top-Down" approach to intestinal fibrosis in mice. Inflamm Bowel Dis. 2012;18:460-471.
15. Boehler A, Chamberlain D, Kesten S, et al. Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation. 1997;64:311-317.
16. Hausmann M, Rechsteiner T, Caj M, et al. A new heterotopic transplant animal model of intestinal fibrosis. Inflamm Bowel Dis. 2013;19:2302-2314.
17. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-1769.
18. Al-Bayati MA, Xie Y, Mohr FC, et al. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol. 2002;64: 517-525.
19. Lee KW, Everett THT, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006;114:1703-1712.
20. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver dis. 2004;36:744-751.
21. Armendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D, et al. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg. 2012; 68:22-28.
22. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20:85-97.
23. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590:400-408.
24. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 1998;83:219-223.
25. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010;9:CD003134.
26. Leeb SN, Vogl D, Falk W, et al. Regulation of migration of human colonic myofibroblasts. Growth Factors. 2002;20:81-91.
27. Pinzani M. Fibrosis in the GI tract: pathophysiology, diagnosis and treatment options. Front Gastrointest Res. 2010;26:15-31.
28. Rieder F, Kessler S, Sans M, et al. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol. 2012;303:G786-G801.
29. Abedi H, Zachary I. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc Res. 1995;30:544-556.
30. Brunton VG, Ozanne BW, Paraskeva C, et al. A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene. 1997;14:283-293.
31. Haq F, Trinkaus-Randall V. Injury of stromal fibroblasts induces phosphorylation of focal adhesion proteins. Curr Eye Res. 1998;17:512-523.
32. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999;71:435-478.
33. Liu YW, Sanders MA, Basson MD. Human Caco-2 intestinal epithelial motility is associated with tyrosine kinase and cytoskeletal focal adhesion kinase signals. J Surg Res. 1998;77:112-118.
34. Sieg DJ, Hauck CR, Schlaepfer DD. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci. 1999; 112 (pt 16):2677-2691.
35. Leeb SN, Vogl D, Gunckel M, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology. 2003;125:1341-1354.
36. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214:199-210.
37. Graham MFBG, Diegelmann RF. Transforming growth factor beta 1 selectively augments collagen synthesis by human intestinal smooth muscle cells. Gastroenterology. 1990;99:447-453.
38. Barnard JA, Beauchamp RD, Coffey RJ, et al. Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci USA. 1989;86:1578-1582.
39. Koyama SY, Podolsky DK. Differential expression of transforming growth factors alpha and beta in rat intestinal epithelial cells. J Clin Invest. 1989;83:1768-1773.
40. Suemori S, Ciacci C, Podolsky DK. Regulation of transforming growth factor expression in rat intestinal epithelial cell lines. J Clin Invest. 1991; 87:2216-2221.
41. Allan JA, Docherty AJ, Barker PJ, et al. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J. 1995;309 (pt 1): 299-306.
42. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73.
43. Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol. 1994;47:113-116.
44. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-822.
45. Baugh MD, Evans GS, Hollander AP, et al. Expression of matrix metalloproteases in inflammatory bowel disease. Ann N Y Acad Sci. 1998;859: 249-253.
46. Gao Q, Meijer MJ, Kubben FJ, et al. Expression of matrix metalloproteinases-2 and-9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis. 2005;37:584-592.
47. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005;129:1991-2008.
48. Santana A, Medina C, Paz-Cabrera MC, et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J gastroenterol. 2006;12:6464-6472.